Meera K Shenoy1, Susan V Lynch. 1. Division of Gastroenterology, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize recent findings on the lung microbiome in HIV-infected patients and associated pulmonary diseases, and the relationship of airway microbial communities to metabolic and immune signatures within this patient population. RECENT FINDINGS: The lung microbiome in HIV infection is a relatively new and rapidly developing field; early studies in the field produced inconclusive evidence as to whether HIV-infection changes the lower airway microbiome. More recent microbiome investigations have addressed these inconsistencies by incorporating systems biology approaches and laboratory models. Several investigations have now identified enrichment of Prevotella, Veillonella, and Streptococcus in the lower airways as consistent correlates of advanced HIV-infection and HIV-associated pulmonary diseases. These bacteria are associated with specific metabolic and immune profiles within the lung and circulation, providing the first indication that the lung microbiome may play a functional role in the pathogenesis of HIV-infection and HIV-associated pulmonary disease. SUMMARY: This review summarizes knowledge to date on the lung microbiome in HIV infection, as well as challenges and accomplishments in the field within the last 2 years. Although the lung microbiome in HIV infection is still an emerging field, recent studies have formed a framework for future functional analysis of microbes in HIV pathogenesis.
PURPOSE OF REVIEW: The purpose of this review is to summarize recent findings on the lung microbiome in HIV-infectedpatients and associated pulmonary diseases, and the relationship of airway microbial communities to metabolic and immune signatures within this patient population. RECENT FINDINGS: The lung microbiome in HIV infection is a relatively new and rapidly developing field; early studies in the field produced inconclusive evidence as to whether HIV-infection changes the lower airway microbiome. More recent microbiome investigations have addressed these inconsistencies by incorporating systems biology approaches and laboratory models. Several investigations have now identified enrichment of Prevotella, Veillonella, and Streptococcus in the lower airways as consistent correlates of advanced HIV-infection and HIV-associated pulmonary diseases. These bacteria are associated with specific metabolic and immune profiles within the lung and circulation, providing the first indication that the lung microbiome may play a functional role in the pathogenesis of HIV-infection and HIV-associated pulmonary disease. SUMMARY: This review summarizes knowledge to date on the lung microbiome in HIV infection, as well as challenges and accomplishments in the field within the last 2 years. Although the lung microbiome in HIV infection is still an emerging field, recent studies have formed a framework for future functional analysis of microbes in HIV pathogenesis.
Authors: Sylvia A D Rofael; James Brown; Elisha Pickett; Margaret Johnson; John R Hurst; David Spratt; Marc Lipman; Timothy D McHugh Journal: EClinicalMedicine Date: 2020-06-27
Authors: Nathalie Rolhion; Benoit Chassaing; Marie-Anne Nahori; Jana de Bodt; Alexandra Moura; Marc Lecuit; Olivier Dussurget; Marion Bérard; Massimo Marzorati; Hannah Fehlner-Peach; Dan R Littman; Andrew T Gewirtz; Tom Van de Wiele; Pascale Cossart Journal: Cell Host Microbe Date: 2019-11-13 Impact factor: 21.023
Authors: Ryan R Cook; Jennifer A Fulcher; Nicole H Tobin; Fan Li; David J Lee; Cora Woodward; Marjan Javanbakht; Ron Brookmeyer; Steve Shoptaw; Robert Bolan; Grace M Aldrovandi; Pamina M Gorbach Journal: Sci Rep Date: 2019-10-16 Impact factor: 4.379
Authors: Sudha Bhadriraju; Douglas W Fadrosh; Susan V Lynch; John Z Metcalfe; Meera K Shenoy; Din L Lin; Kole V Lynch; Kathryn McCauley; Rashida A Ferrand; Edith D Majonga; Grace McHugh; Laurence Huang Journal: Sci Rep Date: 2020-09-30 Impact factor: 4.996